India’s five-year breast cancer survival rate stands at 65.7% for women diagnosed between 2017 and 2021, the World Health Organization’s first country-by-country baseline found in a study published July 8, 2026 in Nature Medicine. The figure trails the global median of 77.8% and the 87.3% rate recorded in high-income countries. WHO modelled survival for all 194 member states, anchoring the Global Breast Cancer Initiative’s benchmark for tracking whether its 2.5% annual mortality reduction target is on track.
A 194-Country Baseline Lands on July 8
A WHO study, the 2017-2021 global breast cancer survival estimates paper, published July 8 in Nature Medicine is the first to estimate five-year breast cancer survival across all 194 member states. The agency pooled registry data from 67 countries with observed cases and modelled the remaining countries using stage at diagnosis, radiotherapy and mammography capacity, access to cancer medicines, and overall adult mortality. Stage at diagnosis emerged as the single strongest survival predictor in the model, the agency said.
Among the 36 fragile and conflict-affected states included in the analysis, only two had any observed registry data, the agency noted. The research project was funded by the Republic of Korea, St. Jude Children’s Research Hospital, and the City Cancer Challenge. WHO worked with member states through a two-phase consultation process to review methodology and incorporate the available national data, the first 194-country five-year breast cancer survival baseline states. Eight million women, mostly in high-income countries, were estimated to be living with breast cancer when the figures were assembled.
Dr Alarcos Cieza, the WHO official who oversees noncommunicable disease management, called survival the most direct cross-country measure of how well health systems detect, diagnose and treat breast cancer. Breast cancer is the most common cancer among women in 158 countries and caused roughly 694,000 deaths globally in 2024, the release said. Many of those deaths occur in countries where most cases still present at advanced stage.
Where 65.7% Falls on the Global Map
The full picture of the 2017-2021 estimates reads as a steep income gradient. The median five-year net survival in high-income countries was 87.3%, the WHO release said. Upper-middle-income countries reached 78.7%, lower-middle-income countries 60.1%, and low-income countries 41.9%, less than half the rate in the richest group. The pattern mirrors the regional gradient and makes clear which countries pulled furthest ahead over the 2017-2021 window.
The regional gradient is just as steep. The Americas led at 88.5%, the European region at 84.0%, the Western Pacific at 81.1%, the South-East Asia region at 66.3%, the Eastern Mediterranean at 61.0%, and the African region at 39.1%. India, classified in the South-East Asia region, registered a national estimate of 65.7%, just below the regional median. Across income groups, the global median of 77.8% sits closest to the upper-middle-income figure of 78.7%. The figures give every country the kind of cross-country baseline the GBCI framework was set up to track, the WHO release noted.
| Group | 5-year net survival |
|---|---|
| WHO Region of the Americas | 88.5% |
| WHO European Region | 84.0% |
| WHO Western Pacific Region | 81.1% |
| WHO South-East Asia Region | 66.3% |
| WHO Eastern Mediterranean Region | 61.0% |
| WHO African Region | 39.1% |
| Global median | 77.8% |
| High-income countries | 87.3% |
| Upper-middle-income countries | 78.7% |
| Lower-middle-income countries | 60.1% |
| Low-income countries | 41.9% |
| India | 65.7% |
Why 65.7% Comes With a Diagnostic Tail
The single strongest predictor in the WHO model is stage at diagnosis. Countries where breast cancer tends to be caught at stage I or II record far higher five-year survival; countries where most cases present at stage III or IV record far lower.
A 2024 study led by K. Sathishkumar and published in the journal Cancer tracked 17,331 women diagnosed between 2012 and 2015 across 11 Indian cancer registries and reported observed five-year survival by stage: 81.0% for localized disease, 65.5% for regional spread, and 18.3% for distant metastasis. The 18.3% distant-metastasis figure is the population the WHO model weights most heavily in a country’s overall survival. Indian registry outcomes from the early-2010s sit just behind the WHO’s modelled 2017-2021 estimate in time. The Sathishkumar paper followed those patients through June 30, 2021, the methodology section states. Beyond stage at diagnosis, the WHO’s main covariates are radiotherapy, mammography and access to cancer medicines, the release noted.
In India, that mix tilts toward late presentation. WHO lists access to radiotherapy, mammography and cancer medicines as the key covariates feeding into the modelled survival estimates for countries that lack complete registry data. India’s cancer-care infrastructure is concentrated in major cities, with rural districts short of pathology, imaging and radiotherapy capacity, public health analyses show.
India runs community-based breast-cancer screening and the federal health insurance scheme Ayushman Bharat-PMJAY, but a large share of cases still present at advanced stage. The WHO baseline ties that presentation pattern to three GBCI operational targets: 60% of invasive breast cancers diagnosed at stage I or II, diagnosis within 60 days of presentation, and 80% or more of patients completing multimodality treatment. India’s 65.7% sits below each of those operational pillars today. Beyond stage, the WHO’s main covariates in the modelled estimates are access to cancer medicines, radiotherapy capacity and mammography capacity.
India Has Already Doubled Survival Since the 1990s
Indian registries record a much longer arc than the new WHO baseline shows. A 2024 National Cancer Registry Programme study led by K. Sathishkumar and published in the journal Cancer, the 2024 Indian cancer registry survival study, found five-year survival of 66.4% for women diagnosed between 2012 and 2015. The same registries had earlier put survival at 31% to 54% for patients diagnosed during the 1990s, the Times of India report noted.
The Sathishkumar study covered 11 geographic areas and recorded wide local variation. Mizoram topped the list at 74.9%, Ahmedabad’s urban registry at 72.7%, Kollam at 71.5%, and Thiruvananthapuram at 69.1%, all above the national average. Pasighat recorded the lowest at 41.9%. Researchers flagged earlier diagnosis and broader access to quality cancer care as the levers the data points to for further improvement. The WHO’s new 194-country baseline extends the same finding to every country the model covers.
Three Pillars the WHO Is Now Measuring
The WHO Global Breast Cancer Initiative, the Global Breast Cancer Initiative program overview, established in 2021, sets out three operational pillars countries are meant to track, with the 2017-2021 baseline as the measuring stick. The broader goal is a 2.5% annual reduction in premature breast cancer mortality, a pace the agency says would save 2.5 million lives by 2040. India’s 65.7% sits inside a health system currently missing all three operational pillars today. The GBCI operational pillars translate the targets into stage, time-to-diagnosis, and treatment-completion terms.
- Stage at diagnosis. 60% of invasive breast cancers diagnosed at stage I or II.
- Timely diagnosis. Diagnosis completed within 60 days of first presentation.
- Treatment completion. 80% or more of patients who need it complete the full course of multimodality treatment.
Together, the three pillars identify where a laggard health system can intervene. Stage at diagnosis sits at the top because it is also the strongest survival predictor in the WHO model. None of the three GBCI pillars is currently met in India, based on the WHO’s modelled Indian estimate and the agency’s own diagnostic-pillar coverage descriptions. The framework treats the pillars as a single composite measure, the WHO release adds. Country-level annual reporting against the three pillars is the GBCI’s core measurement process.
The numbers most exposed to change in India are the proportion of cases caught at stage I or II and the share of patients completing the full course of multimodality treatment. Both are measured directly in the WHO’s next modelling cycle, the release states.
An AIIMS Oncologist Frames the Gap
Indian oncologists read 65.7% as a precise echo of long-running access problems across India’s cancer care continuum. The fuller statement from Indian specialists positions the WHO’s three pillars as the same levers India needs to pull. Indian registry data on stigma, financial barriers and rural access was documented long before the WHO’s 2026 baseline, public health studies show.
“India’s estimated five-year breast cancer survival rate of 65.7% reflects gaps across the cancer care continuum, not just treatment. Survival has improved with community-based screening and Ayushman Bharat-PMJAY, but many women still present with advanced disease due to low awareness, stigma, financial barriers, and delays in diagnosis. Disparities in access to pathology, imaging, radiotherapy, systemic therapy and follow-up care, especially between urban and rural areas, continue to affect outcomes. Strengthening early detection, timely diagnosis and equitable access to quality treatment is essential to improve survival.”
That is from Abhishek Shankar, assistant professor of radiation oncology at AIIMS in New Delhi, in a statement to The Times of India this week. Shankar framed each of the three GBCI pillars (earlier detection, prompt diagnosis, full treatment) as the upstream levers India needs to pull. The WHO baseline now becomes the comparator for any future change in India’s 65.7%, with the next measurement window set to capture women diagnosed after 2021. State-level registry participation tracks the granularity of any India-specific update, since registry coverage remains the model’s anchor input.
Frequently Asked Questions
What is India’s five-year breast cancer survival rate?
The WHO’s first 194-country baseline puts India’s five-year net survival at 65.7% for women diagnosed between 2017 and 2021, the agency said on July 8, 2026.
How does India’s figure compare to the global median?
India’s 65.7% trails the 77.8% global median and the 87.3% rate in high-income countries. The median survival in India’s South-East Asia region was 66.3%, just above India’s national estimate.
Why does India lag behind high-income countries?
The single strongest predictor of survival in the WHO model is stage at diagnosis. Indian cancer registries show 81.0% five-year survival for localized breast cancer, 65.5% for regional spread, and 18.3% for distant metastasis. Late presentation together with limited rural access to radiotherapy and pathology is what the WHO model attributes the gap to.
Has India’s breast cancer survival always been this low?
No. Indian registry data shows wide geographic variation alongside the overall climb. A 2024 study led by K. Sathishkumar and published in Cancer recorded five-year survival of 74.9% in Mizoram, 72.7% in Ahmedabad’s urban registry, and just 41.9% in Pasighat. The same paper found a national average of 66.4% for women diagnosed between 2012 and 2015, up from 31% to 54% in the 1990s.
What is the WHO Global Breast Cancer Initiative target?
The GBCI, established in 2021, targets a 2.5% annual reduction in premature breast cancer mortality by 2040, a pace the agency ties to saving 2.5 million lives. Its three operational pillars spell out what that pace looks like in practice: 60% of invasive breast cancers diagnosed at stage I or II, diagnosis within 60 days of presentation, and 80% of indicated patients completing multimodality treatment.
Disclaimer: This article references peer-reviewed medical and public health data, including WHO modelled estimates and Indian cancer-registry outcomes. Survival figures are accurate as of publication. Readers should consult a qualified medical professional for personal health decisions.
